{"id":6276,"date":"2020-04-30T11:48:11","date_gmt":"2020-04-30T09:48:11","guid":{"rendered":"https:\/\/www.verduci.it\/?p=6276"},"modified":"2025-11-20T09:20:48","modified_gmt":"2025-11-20T08:20:48","slug":"eculizumab-treatment-in-patients-with-covid-19","status":"publish","type":"post","link":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/","title":{"rendered":"Eculizumab treatment in patients with COVID-19"},"content":{"rendered":"<h2>Eculizumab treatment in patients with COVID-19: preliminary results from real life ASL Napoli 2 Nord experience<\/h2>\n<p><strong>Authors:<\/strong> F. Diurno, F.G. Numis, G. Porta, F. Cirillo, S. Maddaluno, A. Ragozzino, P. De Negri, C. Di Gennaro, A. Pagano, E. Allegorico, L. Bressy, G. Bosso, A. Ferrara, C. Serra, A. Montisci, M. D&#8217;Amico, S. Schiano Lo Morello, G. Di Costanzo, A.G. Tucci, P. Marchetti, U. Di Vincenzo, I. Sorrentino, A. Casciotta, M. Fusco, C. Buonerba, M. Berretta, M. Ceccarelli, G. Nunnari, Y. Diessa, S. Cicala, G. Facchini<\/p>\n<p><strong>Affiliation:<\/strong> Department of Emergency and Critical Care, ASL Napoli 2 Nord, \u201cS.M. delle Grazie Hospital\u201d, Pozzuoli (NA), Italy.<br \/>\n  <a href=\"mailto:gaetano.facchini@aslnapoli2nord.it\" title=\"Send an email to Gaetano Facchini\" aria-label=\"Send an email to Gaetano Facchini\">gaetano.facchini@aslnapoli2nord.it<\/a>\n<\/p>\n<h2>Objective<\/h2>\n<p><strong>Objective:<\/strong> SARS-CoV-2\u2013related pneumonia (COVID-19) represents a public health emergency due to its high morbidity and mortality and the absence of specific approved treatments. This case series reports preliminary data on anti-complement C5 therapy (eculizumab) in COVID-19 ICU patients admitted to ASL Napoli 2 Nord.<\/p>\n<h2>Patients and Methods<\/h2>\n<p><strong>Patients and Methods:<\/strong> This case series includes patients with confirmed SARS-CoV-2 infection and severe pneumonia or acute respiratory distress syndrome (ARDS) treated with up to four off-label infusions of eculizumab. All patients also received standard COVID-19 treatments: Enoxaparin 4,000 IU\/day SC, Lopinavir 800 mg\/day + Ritonavir 200 mg\/day, hydroxychloroquine 400 mg\/day, ceftriaxone 2 g\/day IV, vitamin C 6 g\/day for 4 days, and Non-Invasive Ventilation (NIV).<\/p>\n<h2>Results<\/h2>\n<p><strong>Results:<\/strong> Four severe COVID-19 ICU patients were treated with eculizumab. All recovered successfully. Eculizumab produced a marked reduction in inflammatory markers: mean C-reactive protein (CRP) decreased from 14.6 mg\/dl to 3.5 mg\/dl, and mean disease duration was 12.8 days.<\/p>\n<h2>Conclusions<\/h2>\n<p><strong>Conclusions:<\/strong> Eculizumab shows potential as a therapeutic option in severe COVID-19 cases. These preliminary results support its off-label use pending evidence from the ongoing SOLID-C19 clinical trial.<\/p>\n<div class=\"vc_btn3-container verduci-button vc_btn3-center\">\n  <a class=\"vc_general vc_btn3 vc_btn3-size-md vc_btn3-shape-rounded vc_btn3-style-modern\" href=\"https:\/\/www.europeanreview.org\/article\/20875\" target=\"_blank\" rel=\"noopener noreferrer\" aria-label=\"Read the full scientific article about eculizumab treatment in COVID-19\" title=\"Read full article\">Discover more<\/a>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Case series describing four severe ICU COVID-19 patients treated with eculizumab at ASL Napoli 2 Nord: all patients recovered, with marked CRP reduction and a mean disease duration of about 13 days, suggesting a potential role for anti-complement C5 therapy as a therapeutic option.<\/p>\n","protected":false},"author":2883,"featured_media":5567,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[894],"tags":[],"class_list":["post-6276","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Eculizumab treatment in COVID-19 patients \u2013 Preliminary results | Verduci Editore<\/title>\n<meta name=\"description\" content=\"Case series on off-label eculizumab use in severe ICU COVID-19 patients at ASL Napoli 2 Nord, reporting clinical outcomes and reduction of inflammatory markers.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Eculizumab treatment in COVID-19 patients \u2013 Preliminary results | Verduci Editore\" \/>\n<meta property=\"og:description\" content=\"Case series on off-label eculizumab use in severe ICU COVID-19 patients at ASL Napoli 2 Nord, reporting clinical outcomes and reduction of inflammatory markers.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/\" \/>\n<meta property=\"og:site_name\" content=\"Verduci\" \/>\n<meta property=\"article:published_time\" content=\"2020-04-30T09:48:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-20T08:20:48+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-coronavirus.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1920\" \/>\n\t<meta property=\"og:image:height\" content=\"1280\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Verduci\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Verduci\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/\"},\"author\":{\"name\":\"Verduci\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/person\\\/6d04f63706e39a6c3bbd8ad40fadceee\"},\"headline\":\"Eculizumab treatment in patients with COVID-19\",\"datePublished\":\"2020-04-30T09:48:11+00:00\",\"dateModified\":\"2025-11-20T08:20:48+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/\"},\"wordCount\":296,\"publisher\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-coronavirus.jpg\",\"articleSection\":[\"News\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/\",\"name\":\"Eculizumab treatment in COVID-19 patients \u2013 Preliminary results | Verduci Editore\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-coronavirus.jpg\",\"datePublished\":\"2020-04-30T09:48:11+00:00\",\"dateModified\":\"2025-11-20T08:20:48+00:00\",\"description\":\"Case series on off-label eculizumab use in severe ICU COVID-19 patients at ASL Napoli 2 Nord, reporting clinical outcomes and reduction of inflammatory markers.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-coronavirus.jpg\",\"contentUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-coronavirus.jpg\",\"width\":1920,\"height\":1280,\"caption\":\"3D representation of the SARS-CoV-2 coronavirus\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/eculizumab-treatment-in-patients-with-covid-19\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.verduci.it\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Eculizumab treatment in patients with COVID-19\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#website\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/\",\"name\":\"Verduci\",\"description\":\"Editoria Medico Scientifica Internazionale\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.verduci.it\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#organization\",\"name\":\"Verduci Editore s.r.l.\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-editore-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.verduci.it\\\/wp-content\\\/uploads\\\/2020\\\/04\\\/verduci-editore-logo.svg\",\"width\":\"1024\",\"height\":\"1024\",\"caption\":\"Verduci Editore s.r.l.\"},\"image\":{\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.verduci.it\\\/#\\\/schema\\\/person\\\/6d04f63706e39a6c3bbd8ad40fadceee\",\"name\":\"Verduci\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Eculizumab treatment in COVID-19 patients \u2013 Preliminary results | Verduci Editore","description":"Case series on off-label eculizumab use in severe ICU COVID-19 patients at ASL Napoli 2 Nord, reporting clinical outcomes and reduction of inflammatory markers.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/","og_locale":"en_US","og_type":"article","og_title":"Eculizumab treatment in COVID-19 patients \u2013 Preliminary results | Verduci Editore","og_description":"Case series on off-label eculizumab use in severe ICU COVID-19 patients at ASL Napoli 2 Nord, reporting clinical outcomes and reduction of inflammatory markers.","og_url":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/","og_site_name":"Verduci","article_published_time":"2020-04-30T09:48:11+00:00","article_modified_time":"2025-11-20T08:20:48+00:00","og_image":[{"width":1920,"height":1280,"url":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-coronavirus.jpg","type":"image\/jpeg"}],"author":"Verduci","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Verduci","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#article","isPartOf":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/"},"author":{"name":"Verduci","@id":"https:\/\/www.verduci.it\/#\/schema\/person\/6d04f63706e39a6c3bbd8ad40fadceee"},"headline":"Eculizumab treatment in patients with COVID-19","datePublished":"2020-04-30T09:48:11+00:00","dateModified":"2025-11-20T08:20:48+00:00","mainEntityOfPage":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/"},"wordCount":296,"publisher":{"@id":"https:\/\/www.verduci.it\/#organization"},"image":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-coronavirus.jpg","articleSection":["News"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/","url":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/","name":"Eculizumab treatment in COVID-19 patients \u2013 Preliminary results | Verduci Editore","isPartOf":{"@id":"https:\/\/www.verduci.it\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#primaryimage"},"image":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#primaryimage"},"thumbnailUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-coronavirus.jpg","datePublished":"2020-04-30T09:48:11+00:00","dateModified":"2025-11-20T08:20:48+00:00","description":"Case series on off-label eculizumab use in severe ICU COVID-19 patients at ASL Napoli 2 Nord, reporting clinical outcomes and reduction of inflammatory markers.","breadcrumb":{"@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#primaryimage","url":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-coronavirus.jpg","contentUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-coronavirus.jpg","width":1920,"height":1280,"caption":"3D representation of the SARS-CoV-2 coronavirus"},{"@type":"BreadcrumbList","@id":"https:\/\/www.verduci.it\/en\/eculizumab-treatment-in-patients-with-covid-19\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.verduci.it\/en\/"},{"@type":"ListItem","position":2,"name":"Eculizumab treatment in patients with COVID-19"}]},{"@type":"WebSite","@id":"https:\/\/www.verduci.it\/#website","url":"https:\/\/www.verduci.it\/","name":"Verduci","description":"Editoria Medico Scientifica Internazionale","publisher":{"@id":"https:\/\/www.verduci.it\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.verduci.it\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.verduci.it\/#organization","name":"Verduci Editore s.r.l.","url":"https:\/\/www.verduci.it\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.verduci.it\/#\/schema\/logo\/image\/","url":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-editore-logo.svg","contentUrl":"https:\/\/www.verduci.it\/wp-content\/uploads\/2020\/04\/verduci-editore-logo.svg","width":"1024","height":"1024","caption":"Verduci Editore s.r.l."},"image":{"@id":"https:\/\/www.verduci.it\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/www.verduci.it\/#\/schema\/person\/6d04f63706e39a6c3bbd8ad40fadceee","name":"Verduci"}]}},"_links":{"self":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts\/6276","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/users\/2883"}],"replies":[{"embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/comments?post=6276"}],"version-history":[{"count":4,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts\/6276\/revisions"}],"predecessor-version":[{"id":10604,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/posts\/6276\/revisions\/10604"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/media\/5567"}],"wp:attachment":[{"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/media?parent=6276"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/categories?post=6276"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.verduci.it\/en\/wp-json\/wp\/v2\/tags?post=6276"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}